PharmaVentures

Adrian Dawkes talks to PharmaVentures' Founder and CEO, Dr Fintan Walton, about the importance of strategy and preparation in today's deal making space. In the competitive, fast-paced environment of deal making within the life sciences industry, if you fail to prepare, then you must prepare to fail. Tune in to help assemble your strategy for success.

Join Adrian Dawkes, Managing Director at PharmaVentures, for this podcast episode exploring how the pharmaceutical manufacturing sector is evolving in response to shifting global pressures. Our experts, Ross Jenkins and Dr Gurdas Singh, unpack the critical changes shaping the industry.

Adrian Dawkes talks to recently appointed PharmaVentures' Vice President, Samara Ferguson, about a hot, often controversial topic: the price of medicines.

Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about how companies can navigate risk and even deploy new strategies in times of increased uncertainty. With the threat of tariffs, a global trade war and unease in the financial markets this podcast explores the ways companies can gain advantage over their competitors and survive when geo-politics and high levels of volatility in...

Fintan Walton, founder and CEO of PharmaVentures chairs a round table discussion on this pressing issue.   Featuring; Jim Gale. Managing Partner, Signet Healthcare Partners. A New York based Private equity firm with a wide portfolio including API medchem, Pharma Services and CDMO businesses. Andreas Raabe: Founder & CEO of Adragos Pharma, a CDMO manufacturing in the EU and Japan. Frank Dollard...

Adrian Dawkes talks to PharmaVentures Founder and CEO Fintan Walton about his experience from over 30 years of dealmaking. In particular, why innovator biotechs and their investors are weaker when they underestimate the significance of both understanding and communicating their commercial strategy for their lead assets in negotiations. Hear about: • Failing to understand the inherent risks at the...

Listen as Adrian Dawkes talks to Kurt Herpel, CEO and Klaus Kratochwill, CSO of Delta 4, an Austrian /Swiss based AI tech company. Hear how their AI journey began more than 20 years ago and how the company developed into a key player in AI drug discovery. Hear how their clients are already benefiting from AI. You will hear their insights into; • Where AI is benefiting drug discovery processes toda...

Listen as Soren Demin draws on his 20 years of M&A experience to provide insight into the current Pharma/Biotech M&A landscape. Key topics include; Is the M&A landscape recovering and will we see record activity again? How has the big pharma model changed and what is the impact on deal making? What is the direction of travel for deal volumes and values? How do biotechs position themsel...

Listen as Andreas Katsiamides talks with Adrian Dawkes about the future of diagnostics and the impact on deals. They discuss: Technological advances in diagnostics, such as artificial intelligence (AI), next-generation sequencing (NGS) and polymerase chain reaction (PCR) testing Its application to specific medical models and therapy areas – including personalised medicine, oncology, and Alzheimer’...

Listen as Colin McCall, Partner - Life Sciences and Deep Tech at Taylor Wessing, and Oliver Pumfrey, Managing Director at FTI Consulting, talk with Adrian Dawkes about law and tax during the licensing and M&A deal making process. They discuss a range of topics where different advisors use their expertise to help you achieve the best deal and avoid pitfalls in the future:   The deal stages when...

Once you have identified an asset you want to acquire or partner, what happens next?   In this podcast, Ralph Hughes takes the listener through the process of commercial due diligence and evaluation, including the key stakeholders and insights needed to understand whether the asset is going to achieve strong performance in the marketplace.   Ralph talks to Adrian Dawkes about the different compone...

Listen as Andrew Guise gives key insight into the deal making landscape - asset value, accessing the market, positioning and the actual deal process in the current economic climate - from the unique position standing astride both the financial world and the technical world translating science into value.   About the Interviewee: Andrew Guise is a Managing Director at PharmaVentures and is a member...

Listen as Jansen Jacob, Frank Dollard and Steve Garland discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice;  how the importance of quality and efficiency, including moves towards new low-cost regions in the West, are reducing risk for manufacturers whilst governments are trying to squeeze...

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, discusses the 4 common mistakes being made in partnering and how to avoid them.   Fintan provides insight into how to achieve successful deal outcomes by avoiding risks along the clinical, commercial and regulatory pathway, and what fact-based data you need to get your drug to market with the right partner at the right price.   About the In...

Listen as Ralph Hughes, PharmaVentures’ Pricing and Market Access expert, talks with Adrian Dawkes about how you can reduce the risk when you want to get your asset onto the market and get ahead of the competition.   Understanding incentives, perspectives and funding flows can lead to better pricing and development strategies. Understanding payer perspectives can help you define market positioning...

Listen as Ben Jacoby, Regulatory Expert, talks with Adrian Dawkes about the transition to the new regulations in Europe and UK: Can existing products continue to be sold? What will global manufacturers need to do? What is the impact for companion diagnostics being used alongside drugs in clinical trials? How is the environment in Great Britain different, and what does this mean for innovators? Wha...

Listen as JungHyun Eom describes the Korean partnering opportunity for western biopharma companies and her exciting new role establishing PharmaVentures’ office in Seoul to support current and prospective clients in the wider APAC region, serving as the bridge between the innovation in Asia and its commercialisation to the rest of the world. Hosted by Adrian Dawkes.

In this podcast, PharmaVentures’ deal experts discuss the process of helping clients in the life sciences industry acquire or license assets or rights in specific markets or whole companies. Hosted by Adrian Dawkes.

Listen as Stephen Waterman and Kyriakos Tzafestas describe how PharmaVentures’ real-world experience combines with valuation models, in-depth commercial insight including rigorous pricing, and best quality data sources to value companies, assets and pharma licensing deals to give their clients the confidence to negotiate the most robust and defensible positions in deal making to secure the most im...

Listen as Fintan Walton, PharmaVentures’ CEO and Founder, reflects on this year’s deal trends in M&A, Licensing and Fundraising, considers the significant macroeconomic events, and offers insight into what impact they may have on the global pharma and biotech industry in 2023. Hosted by Adrian Dawkes.

Listen as Jansen Jacob and Steve Garland discuss how the future role of CDMOs in biopharmaceutical manufacturing will be affected by the challenges of cost, new modalities and new innovation; cell and gene therapy (CGT), and personalised medicine. Hosted by Adrian Dawkes.

Listen as PharmaVentures’ Pricing and Market Access expert, Ralph Hughes, recommends elements of a robust plan to help you achieve the best pricing and market access for your drug, and to give you the increased confidence to strengthen your position during deal making negotiations. Hosted by Adrian Dawkes.